Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy

I F Tannock; G Bouche; D A Goldstein; Y Goto; A S Lichter; K Prabhash; P Ranganathan; L B Saltz; G S Sonke; G W Strohbehn; R von Moos; M J Ratain

doi:10.1016/j.annonc.2023.05.006

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy

Ann Oncol. 2023 Aug;34(8):638-644. doi: 10.1016/j.annonc.2023.05.006. Epub 2023 May 23.

Authors

I F Tannock¹, G Bouche², D A Goldstein³, Y Goto⁴, A S Lichter⁵, K Prabhash⁶, P Ranganathan⁶, L B Saltz⁷, G S Sonke⁸, G W Strohbehn⁹, R von Moos¹⁰, M J Ratain¹¹

Affiliations

¹ Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada; Optimal Cancer Care Alliance, Ann Arbor, USA. Electronic address: ian.tannock@uhn.ca.
² Anticancer Fund, Meise, Belgium; Medical Research Council Clinical Trials Unit at University College London, London, UK.
³ Optimal Cancer Care Alliance, Ann Arbor, USA; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁴ Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
⁵ Optimal Cancer Care Alliance, Ann Arbor, USA.
⁶ Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
⁷ Optimal Cancer Care Alliance, Ann Arbor, USA; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
⁸ Department of Medical Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, Amsterdam, The Netherlands; University of Amsterdam, Amsterdam, The Netherlands.
⁹ Optimal Cancer Care Alliance, Ann Arbor, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, USA; Section of Hematology Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, USA; Veterans Affairs Center for Clinical Management Research, Ann Arbor, USA.
¹⁰ Department of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland; SAKK Competence Center, Bern, Switzerland.
¹¹ Optimal Cancer Care Alliance, Ann Arbor, USA; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, USA.

PMID: 37230253
DOI: 10.1016/j.annonc.2023.05.006

No abstract available

Publication types

Editorial

MeSH terms

Cost-Benefit Analysis
Humans
Neoplasms* / drug therapy
Patient-Centered Care